-

05:52:54 AM

Latest BIIB Stock Market News

BIIB - Biogen Inc

06/17/21 7:30 AM

Nasdaq : BIIB

Biogen Announces First Patient Dosed in Phase 3 Systemic Lupus Erythematosus Study

Global Phase 3 TOPAZ-1 study will evaluate the efficacy and safety of BIIB059, as compared to placebo, in active systemic lupus erythematosus (SLE) , a debilitating autoimmune disease which has limited treatment options Positive Phase 2 LILAC study efficacy results support the further evaluation of

RHEA-AI

neutral

06/16/21 4:30 PM

Nasdaq : BIIB

Biogen Announces Topline Results From Phase 2 Study of Gosuranemab, an Anti-Tau Antibody, for Alzheimer’s Disease

Biogen Inc. (Nasdaq: BIIB) today announced topline results from its Phase 2 TANGO study of gosuranemab (BIIB092), an investigational anti-tau antibody that was being evaluated as a potential treatment for Alzheimer’s disease. Gosuranemab did not

RHEA-AI

neutral

06/15/21 6:30 AM

Nasdaq : SAGE, BIIB

Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder

Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today announced that the WATERFALL Study in patients with MDD met its primary endpoint with zuranolone (SAGE-217/BIIB125) 50 mg showing statistically significant improvement in depressive symptoms compared with placebo at Day 15

RHEA-AI

neutral

06/15/21 6:30 AM

Nasdaq : BIIB

Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder

At the Day 15 primary endpoint, zuranolone 50 mg showed a statistically significant and clinically meaningful reduction in depressive symptoms as measured by HAMD-17 (p=0.0141) compared to placebo Rapid onset of treatment effect was seen in HAMD-17 results at Days 3, 8, and 12 Patients with a

RHEA-AI

neutral

06/14/21 4:06 PM

Nasdaq : BIIB

Biogen Announces Topline Results from Phase 3 Gene Therapy Study in Choroideremia

Biogen Inc. (Nasdaq: BIIB) today announced topline

RHEA-AI

neutral

06/10/21 4:06 PM

Nasdaq : BIIB

Biogen Announces Investor Day on September 21, 2021

Biogen Inc. (Nasdaq: BIIB) announced today that it will hold an Investor Day focused on its broad pipeline across neuroscience and related therapeutic adjacencies. The event will be webcast live on September 21, 2021 at 10:00 a.m. ET. Further

RHEA-AI

neutral

06/10/21 7:30 AM

Nasdaq : BIIB

New Data at Cure SMA 2021 Highlight the Long-Term Efficacy of SPINRAZA® (nusinersen) and Biogen’s Commitment to Innovation in SMA Therapy

New data analysis suggests an investigational higher dose of SPINRAZA may lead to clinically meaningful improvements in motor function A NURTURE study analysis shows 92 percent of children who initiated SPINRAZA treatment as pre-symptomatic infants maintained the ability to swallow after

RHEA-AI

positive

06/07/21 1:01 PM

Nasdaq : BIIB

Biogen and Eisai launch multiple initiatives to help patients with Alzheimer’s disease access ADUHELM™

Programs now available to support patients and families with their treatment journey Collaborations with Veterans Health Administration, CVS Health and NAFC focused on health disparities in underserved communities Value-based agreements in progress with Cigna and other payers CAMBRIDGE, Mass. and

RHEA-AI

neutral

06/07/21 1:00 PM

Nasdaq : BIIB

FDA grants accelerated approval for ADUHELM™ as the first and only Alzheimer’s disease treatment to address a defining pathology of the disease

Biogen (Nasdaq: BIIB) and

RHEA-AI

neutral

06/01/21 7:30 AM

Nasdaq : BIIB

Biogen and Bio-Thera Announce Positive Results From Phase 3 Study of BAT1806, a Proposed Biosimilar Referencing Actemra® (Tocilizumab)

Biogen Inc. (Nasdaq: BIIB) and Bio-Thera Solutions, Ltd.

RHEA-AI

positive

1 2 3 4 5 6 7 Next

BIIB Data

industryBiological Product (except Diagnostic) Manufacturing
websitewww.biogen.com
ceoMichel Vounatsos
security nameBiogen Inc
issue typecs
sectorManufacturing
sic code2836
employees7300
tagsHealth Technology,Biotechnology,Manufacturing,Biological Product (except Diagnostic) Manufacturing
address225 Binney St
address2
stateMassachusetts
cityCambridge
zip02142-1031
countryUS
phone17814642000

BIIB Description:

At Biogen, mission is clear: company is pioneer in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world's first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer's disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, neuropsychiatry, immunology, acute neurology and neuropathic pain.